EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Res Treat
Prif Awduron: Park, Sehhoon, Ku, Bo Mi, Jung, Hyun Ae, Sun, Jong-Mu, Ahn, Jin Seok, Lee, Se-Hoon, Park, Keunchil, Ahn, Myung-Ju
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Korean Cancer Association 2020
Pynciau:
Case Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577810/
https://ncbi.nlm.nih.gov/pubmed/32599977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2020.278
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg